← Atlas Theme · spans 1 topics
Dense patent thickets delay generic drug competition far beyond compound expirations.
Although challengers may file early generic applications, branded innovators deploy expansive patent trees to trigger multi-year regulatory stays that block low-cost market entry.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
GLP-1 Cross-Sector Effects
Eli Lilly Commands Q2 2026 with Blockbuster Earnings: Tirzepatide Surges as Oral Foundayo Misses Slightly Eli Lilly relies on Paragraph IV patent litigation and subsequent FDA stays to defend its multi-billion-dollar tirzepatide franchise against generic filings from Sandoz and Hybio.
GLP-1 Cross-Sector Effects
Eli Lilly Launches Massive Patent Litigation Campaign Against Generic Tirzepatide Applicants, Triggering 30-Month FDA Stay Eli Lilly successfully used the Hatch-Waxman Act's 45-day litigation window to force a 30-month regulatory delay on generic competitors, shielding its blockbuster tirzepatide.